{
  "id": "622dfb133a8413c6530000a8",
  "type": "factoid",
  "question": "What is the drug  gantenerumab targeting?",
  "ideal_answer": "Gantenerumab significantly reduced amyloid plaques, cerebrospinal fluid total tau, and phospho-tau181 and attenuated increases of neurofilament light chain.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/33336218",
    "http://www.ncbi.nlm.nih.gov/pubmed/34198582",
    "http://www.ncbi.nlm.nih.gov/pubmed/34155411"
  ],
  "snippets": [
    {
      "text": "Gantenerumab significantly reduced amyloid plaques, cerebrospinal fluid total tau, and phospho-tau181 and attenuated increases of neurofilament light chain. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34155411",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The late-stage agents with positive clinical or biomarker data include four antibodies that engage A\u03b2 oligomers (aducanumab, lecanemab, gantenerumab, and donanemab) and ALZ-801, an oral agent that fully blocks the formation of A\u03b2 oligomers at the clinical dose.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34198582",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Reduction in Amyloid Burden with Subcutaneous Gantenerumab.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33336218",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "These results demonstrate that prolonged gantenerumab treatment, at doses up to 1200 mg, reduces amyloid plaque levels below the amyloid positivity threshold. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33336218",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": [],
  "exact_answer": "Gantenerumab significantly reduced amyloid plaques, cerebrospinal fluid total tau, and phospho-tau181 and attenuated increases of neurofilament light chain."
}